Invesaro

Stocks PLX Earnings

Earnings

Protalix BioTherapeutics, Inc. (PLX) earnings

Quarterly results of Protalix BioTherapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when PLX files with the SEC.

Next earnings date

Protalix BioTherapeutics, Inc. is expected to report around November 12, 2026. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q2 FY2026

In Q2 FY2026 (ended June 30, 2026) Protalix BioTherapeutics, Inc. reported revenue of $19.9M (+27.1% on the same quarter a year earlier) and net income of $3.8M (+2,203% on the same quarter a year earlier).

Diluted earnings per share were $0.05.

Filed with the SEC on August 12, 2026.

Revenue by quarter
Q3 24: $18M $18M Q3 24Q4 24: $18.2M $18.2M Q4 24Q1 25: $10.1M $10.1M Q1 25Q2 25: $15.7M $15.7M Q2 25Q3 25: $17.9M $17.9M Q3 25Q4 25: $9.1M $9.1M Q4 25Q1 26: $33.8M $33.8M Q1 26Q2 26: $19.9M $19.9M Q2 26
Net income by quarter
Q3 24: $3.2M $3.2M Q3 24Q4 24: $6.5M $6.5M Q4 24Q1 25: -$3.6M -$3.6M Q1 25Q2 25: $164K $164K Q2 25Q3 25: $2.4M $2.4M Q3 25Q4 25: -$5.5M -$5.5M Q4 25Q1 26: $18.3M $18.3M Q1 26Q2 26: $3.8M $3.8M Q2 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q2 FY2026June 30, 2026$19.9M+27.1%$3.8M$0.05
Q1 FY2026March 31, 2026$33.8M+233.7%$18.3M$0.22
Q4 FY2025December 31, 2025$9.1M-49.9%-$5.5M-
Q3 FY2025September 30, 2025$17.9M-0.6%$2.4M$0.03
Q2 FY2025June 30, 2025$15.7M-$164K$0.00
Q1 FY2025March 31, 2025$10.1M--$3.6M-$0.05
Q4 FY2024December 31, 2024$18.2M-$6.5M-
Q3 FY2024September 30, 2024$18M-$3.2M$0.03

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Protalix BioTherapeutics, Inc.'s next earnings date?

Protalix BioTherapeutics, Inc. is expected to report around November 12, 2026. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Protalix BioTherapeutics, Inc.'s latest quarterly results?

For Q2 FY2026, which ended June 30, 2026, Protalix BioTherapeutics, Inc. reported revenue of $19.9M and net income of $3.8M (+2,203% on the same quarter a year earlier). The figures come from its filing with the SEC.

Is Protalix BioTherapeutics, Inc.'s revenue growing?

Revenue in Q2 FY2026 was $19.9M, up 27.1% from $15.7M in the same quarter a year earlier.

Get an email when PLX reports

Follow PLX and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when PLX files with the SEC.

Source: quarterly figures Protalix BioTherapeutics, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Protalix BioTherapeutics, Inc.